Finally, SHR-A1921, a novel ADC that binds an anti-TROP2 monoclonal antibody to a topoisomerase I inhibitor via a tetrapeptide linker, demonstrated encouraging anti-cancer activity and manageable safety in heavily pretreated patients with platinum-resistant ovarian cancer in a phase I study (NCT05154604) [114]. Here, TACSTD2 is linked to cancer.